Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy

American Journal of Physiology - Renal Physiology

Volumn 297, Issue 4, 2009, Pages

  Pang, Maoyin ^a   Kothapally, Jagan ^a   Mao, Haiping ^b   Tolbert, Evelyn ^a   Ponnusamy, Murugavel ^a   Chin, Y Eugene ^a   Zhuang, Shougang ^a  

^a BROWN UNIVERSITY   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Histone deacetylase; Renal interstitial fibroblasts; STAT3; Trichostatin A; Unilateral ureteral obstruction

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CASPASE 3; FIBRONECTIN; HISTONE DEACETYLASE INHIBITOR; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; STAT3 PROTEIN; TRICHOSTATIN A;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL DEATH; CELL LINE; CONTROLLED STUDY; DRUG INHIBITION; FIBROBLAST; KIDNEY FIBROSIS; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; URETER OBSTRUCTION;

EID: 70349636576     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00282.2009     Document Type: Article

References (53)

1. Arany I, Herbert J, Herbert Z, Safirstein RL. Restoration of CREB function ameliorates cisplatin cytotoxicity in renal tubular cells. Am J Physiol Renal Physiol 294: F577-F581, 2008.
2. Arany I, Megyesi JK, Nelkin BD, Safirstein RL. STAT3 attenuates EGFR-mediated ERK activation and cell survival during oxidant stress in mouse proximal tubular cells. Kidney Int 70: 669-674, 2006. (Pubitemid 44215341)
3. Bascands JL, Schanstra JP. Obstructive nephropathy: insights from genetically engineered animals. Kidney Int 68: 925-937, 2005. (Pubitemid 43246409)
4. Bieliauskas AV, Pflum MK. Isoform-selective histone deacetylase inhibitors. Chem Soc Rev 37: 1402-1413, 2008.
5. Bob FR, Gluhovschi G, Herman D, Potencz E, Gluhovschi C, Trandafirescu V, Schiller A, Petrica L, Velciov S, Bozdog G, Vernic C. Histological, immunohistochemical and biological data in assessing interstitial fibrosis in patients with chronic glomerulonephritis. Acta Histochem 110: 196-203, 2008.
6. Buglio D, Georgakis GV, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ, Younes A. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 112: 1424-1433, 2008.
7. Catania A, Iavarone C, Carlomagno SM, Chiariello M. Selective transcription and cellular proliferation induced by PDGF require histone deacetylase activity. Biochem Biophys Res Commun 343: 544-554, 2006.
8. Chen Z, Han ZC. STAT3: a critical transcription activator in angiogenesis. Med Res Rev 28: 185-200, 2008. (Pubitemid 351281185)
9. De Heer E, Sijpkens YW, Verkade M, den Dulk M, Langers A, Schutrups J, Bruijn JA, van Es LA. Morphometry of interstitial fibrosis. Nephrol Dial Transplant 15, Suppl 6: 72-73, 2000.
10. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370: 737-749, 2003. (Pubitemid 36399066)
11. Dong G, Wang L, Wang CY, Yang T, Kumar MV, Dong Z. Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents. J Pharmacol Exp Ther 325: 978-984, 2008. (Pubitemid 351724333)
12. el Nahas M, Muchaneta-Kubara EC, Tamimi N, Goumenos D. Glomerulosclerosis: the role of interstitial myofibroblasts in its progression. Curr Top Pathol 93: 167-171, 1999.
13. Gallo P, Latronico MV, Gallo P, Grimaldi S, Borgia F, Todaro M, Jones P, Gallinari P, De Francesco R, Ciliberto G, Steinkuhler C, Esposito G, Condorelli G. Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc Res 80: 416-424, 2008.
14. Gao SP, Bromberg JF. Touched and moved by STAT3. Sci STKE 2006: pe30, 2006.
15. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111: 1060-1066, 2008. (Pubitemid 351213383)
16. Hammond JW, Cai D, Verhey KJ. Tubulin modifications and their cellular functions. Curr Opin Cell Biol 20: 71-76, 2008.
17. Hildmann C, Riester D, Schwienhorst A. Histone deacetylases - an important class of cellular regulators with a variety of functions. Appl Microbiol Biotechnol 75: 487-497, 2007. (Pubitemid 46776553)
18. Huang L. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. J Cell Physiol 209: 611-616, 2006. (Pubitemid 44665677)
19. Imai N, Hishikawa K, Marumo T, Hirahashi J, Inowa T, Matsuzaki Y, Okano H, Kitamura T, Salant D, Fujita T. Inhibition of histone deacetylase activates side population cells in kidney and partially reverses chronic renal injury. Stem Cells 25: 2469-2475, 2007. (Pubitemid 47582739)
20. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 110: 341-350, 2002. (Pubitemid 34847966)
21. Kee HJ, Sohn IS, Nam KI, Park JE, Qian YR, Yin Z, Ahn Y, Jeong MH, Bang YJ, Kim N, Kim JK, Kim KK, Epstein JA, Kook H. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 113: 51-59, 2006. (Pubitemid 43958488)
22. Klampfer L, Huang J, Swaby LA, Augenlicht L. Requirement of histone deacetylase activity for signaling by STAT1. J Biol Chem 279: 30358-30368, 2004. (Pubitemid 38937963)
23. Kramer OH, Knauer SK, Greiner G, Jandt E, Reichardt S, Guhrs KH, Stauber RH, Bohmer FD, Heinzel T. A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev 23: 223-235, 2009.
24. Kuratsune M, Masaki T, Hirai T, Kiribayashi K, Yokoyama Y, Arakawa T, Yorioka N, Kohno N. Signal transducer and activator of transcription 3 involvement in the development of renal interstitial fibrosis after unilateral ureteral obstruction. Nephrology (Carlton) 12: 565-571, 2007. (Pubitemid 350059135)
25. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, Seiser C. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 21: 2672-2681, 2002. (Pubitemid 34619383)
26. Lee MJ, Kim YS, Kummar S, Giaccone G, Trepel JB. Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol 20: 639-649, 2008.
27. Leng C, Gries M, Ziegler J, Lokshin A, Mascagni P, Lentzsch S, Mapara MY. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp Hematol 34: 776-787, 2006. (Pubitemid 43737091)
28. Li R, Yang N, Zhang L, Huang Y, Zhang R, Wang F, Luo M, Liang Y, Yu X. Inhibition of Jak/STAT signaling ameliorates mice experimental nephrotic syndrome. Am J Nephrol 27: 580-589, 2007. (Pubitemid 350014945)
29. Liapis H, Barent B, Steinhardt GF. Extracellular matrix in fetal kidney after experimental obstruction. J Urol 166: 1433-1438, 2001. (Pubitemid 32862209)
30. Liu F, Levin MD, Petrenko NB, Lu MM, Wang T, Yuan LJ, Stout AL, Epstein JA, Patel VV. Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin. J Mol Cell Cardiol 45: 715-723, 2008.
31. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 15: 1-12, 2004. (Pubitemid 38020692)
32. Mattagajasingh I, Kim CS, Naqvi A, Yamamori T, Hoffman TA, Jung SB, DeRicco J, Kasuno K, Irani K. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci USA 104: 14855-14860, 2007. (Pubitemid 350003232)
33. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379: 645-648, 1996. (Pubitemid 26053453)
34. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem 40: 1-13, 2005.
35. Moradei O, Vaisburg A, Martell RE. Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents. Curr Top Med Chem 8: 841-858, 2008. (Pubitemid 351984708)
36. Mottet D, Castronovo V. Histone deacetylases: target enzymes for cancer therapy. Clin Exp Metastasis 25: 183-189, 2008.
37. Neilson EG. Mechanisms of disease: fibroblasts - a new look at an old problem. Nat Clin Pract Nephrol 2: 101-108, 2006. (Pubitemid 43355218)
38. Nishitani Y, Iwano M, Yamaguchi Y, Harada K, Nakatani K, Akai Y, Nishino T, Shiiki H, Kanauchi M, Saito Y, Neilson EG. Fibroblast-specific protein 1 is a specific prognostic marker for renal survival in patients with IgAN. Kidney Int 68: 1078-1085, 2005. (Pubitemid 43246424)
39. O'Shea JJ, Kanno Y, Chen X, Levy DE. Cell signaling. Stat acetylation - a key facet of cytokine signaling? Science 307: 217-218, 2005. (Pubitemid 40116227)
40. Rombouts K, Niki T, Greenwel P, Vandermonde A, Wielant A, Hellemans K, De Bleser P, Yoshida M, Schuppan D, Rojkind M, Geerts A. Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-beta(1)-induced fibrogenesis in skin fibroblasts. Exp Cell Res 278: 184-197, 2002. (Pubitemid 35002103)
41. Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser C, Chiocca S. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 27: 4784-4795, 2007. (Pubitemid 47016131)
42. Starai VJ, Celic I, Cole RN, Boeke JD, Escalante-Semerena JC. Sir2-dependent activation of acetyl-CoA synthetase by deacetylation of active lysine. Science 298: 2390-2392, 2002. (Pubitemid 36014212)
43. Tang X, Gao JS, Guan YJ, McLane KE, Yuan ZL, Ramratnam B, Chin YE. Acetylation-dependent signal transduction for type I interferon receptor. Cell 131: 93-105, 2007. (Pubitemid 47498527)
44. Tong JK. Dissecting histone deacetylase function. Chem Biol 9: 668-670, 2002.
45. Truong LD, Choi YJ, Tsao CC, Ayala G, Sheikh-Hamad D, Nassar G, Suki WN. Renal cell apoptosis in chronic obstructive uropathy: the roles of caspases. Kidney Int 60: 924-934, 2001. (Pubitemid 34205792)
46. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH, Mariadason JM. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281: 13548-13558, 2006. (Pubitemid 43855268)
47. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199-210, 2008.
48. Yang J, Liu Y. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol 13: 96-107, 2002. (Pubitemid 34042016)
49. Yang N, Luo M, Li R, Huang Y, Zhang R, Wu Q, Wang F, Li Y, Yu X. Blockage of JAK/STAT signalling attenuates renal ischaemia-reperfusion injury in rat. Nephrol Dial Transplant 23: 91-100, 2008. (Pubitemid 351767355)
50. Yang XJ, Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell 31: 449-461, 2008.
51. Yoshikawa M, Hishikawa K, Marumo T, Fujita T. Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol 18: 58-65, 2007. (Pubitemid 46053422)
52. Zhang G, Kim H, Cai X, Lopez-Guisa JM, Carmeliet P, Eddy AA. Urokinase receptor modulates cellular and angiogenic responses in obstructive nephropathy. J Am Soc Nephrol 14: 1234-1253, 2003. (Pubitemid 36514665)
53. Zoja C, Abbate M, Remuzzi G. Progression of chronic kidney disease: insights from animal models. Curr Opin Nephrol Hypertens 15: 250-257, 2006. (Pubitemid 43755799)